AACR 2022 | Future research directions for the novel PD-1 and CTLA-4 bispecific checkpoint inhibitor, MEDI5752

Ben Tran, MBBS, FRACP, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia, outlines the future research directions for MEDI5752, a novel PD-1 and CTLA-4 bispecific checkpoint inhibitor for advanced solid tumors. MEDI5752 is now being explored at 500mg and 750mg in patients with non-small cell lung cancer and renal cell cancer. Also, data from investigations of MEDI5752 in patients with kidney cancer will be presented at the American Society of Clinical Oncology (ASCO) annual meeting. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.